Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
In remarks reported by Yahoo Finance, Moderna’s chief executive said China is catching up in messenger RNA technology, raising questions about how the mRNA field will be shaped as manufacturing scales and rivals expand.
THE APEX TIMES
THE APEX TIMES
Shares of Johnson & Johnson have climbed more than 54% over the past year and recently cleared a key FDA-related milestone, while the company also lifted its outlook. Even so, investors are weighing how much upside remains after a strong run.
THE APEX TIMES
Yahoo Finance reports a sharp rise in Moderna’s stock following a Wolfe upgrade that put the company’s cancer-stage programs back in investors’ focus.
THE APEX TIMES
An investor letter published for the second quarter of 2026 highlights a recovery narrative around UnitedHealth Group and frames the fund’s recent results in performance terms.
THE APEX TIMES
A Yahoo Finance roundup framed Pfizer’s latest-quarter narrative within the wider branded pharmaceuticals earnings read-through, highlighting how investors are comparing results across a group of large-cap drugmakers.
THE APEX TIMES
A market discussion of Moderna’s cancer-vaccine work, tied to Merck’s personalized approach, is prompting fresh questions about timeline, clinical momentum, and whether the stock has already absorbed the upside implied by a potentially large oncology market.
THE APEX TIMES
The company’s oral obesity franchise extends beyond the U.S., but how European health systems reimburse the therapy may decide whether the expansion meaningfully lifts results.
THE APEX TIMES
Moderna shares surged roughly 11% in a move reported as occurring with no accompanying company news, while BioNTech’s performance lagged the moment’s momentum. Traders are now asking whether the market is moving toward a single favored mRNA name, or simply repricing near-term risk across the platform.
THE APEX TIMES
In Q2 2026, both Eli Lilly and Novo Nordisk stayed at the center of the weight-loss drug race, but their latest moves diverged sharply: one company raised guidance while the other announced layoffs, pipeline write-downs, and a major price cut.
